{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:04:21Z","timestamp":1782144261834,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clim.2021.108830","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T02:20:00Z","timestamp":1629771600000},"page":"108830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cellular changes in eculizumab early responders with generalized myasthenia gravis"],"prefix":"10.1016","volume":"231","author":[{"given":"Yingkai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2021.108830_bb0005","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.clim.2021.108830_bb0010","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2021.108830_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2021.108830_bb0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1196\/annals.1254.057","article-title":"A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clim.2021.108830_bb0025","doi-asserted-by":"crossref","first-page":"577279","DOI":"10.1016\/j.jneuroim.2020.577279","article-title":"Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis","volume":"345","author":"Li","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2021.108830_bb0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni1467","article-title":"Surface phenotype and antigenic specificity of human interleukin 17\u2013producing T helper memory cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2021.108830_bb0035","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry"},{"key":"10.1016\/j.clim.2021.108830_bb0040","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2002-02-0657","article-title":"Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1)","volume":"100","author":"Voehringer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clim.2021.108830_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clim.2021.108830_bb0050","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clim.2021.108830_bb0055","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1164\/rccm.200503-334OC","article-title":"A protective role for the fifth complement component (c5) in allergic airway disease","volume":"173","author":"Drouin","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.clim.2021.108830_bb0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/79759","article-title":"Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma","volume":"1","author":"Karp","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2021.108830_bb0065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nm0402-373","article-title":"Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection","volume":"8","author":"Kopf","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2021.108830_bb0070","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.170.2.788","article-title":"Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection","volume":"170","author":"Suresh","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108830_bb0075","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.immuni.2008.02.001","article-title":"Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells","volume":"28","author":"Strainic","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2021.108830_bb0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1084\/jem.20121525","article-title":"Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells","volume":"210","author":"Kwan","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2021.108830_bb0085","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.4049\/jimmunol.180.9.5882","article-title":"IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production","volume":"180","author":"Liu","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108830_bb0090","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-gamma, and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108830_bb0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2013.12.005","article-title":"Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis","volume":"52","author":"Yi","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2021.108830_bb0100","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/j.1600-6143.2011.03561.x","article-title":"Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice","volume":"11","author":"Raedler","year":"2011","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"key":"10.1016\/j.clim.2021.108830_bb0105","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.1300847","article-title":"Cutting edge: receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells","volume":"190","author":"van der Touw","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108830_bb0110","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.20092301","article-title":"Complement drives Th17 cell differentiation and triggers autoimmune arthritis","volume":"207","author":"Hashimoto","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2021.108830_bb0115","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.4049\/jimmunol.177.8.5145","article-title":"High cytotoxic and specific migratory potencies of senescent CD8+ CD57+ cells in HIV-infected and uninfected individuals","volume":"177","author":"Le Priol","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108830_bb0120","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2010-04-282301","article-title":"CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset","volume":"116","author":"Lopez-Verges","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clim.2021.108830_bb0125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00262-016-1803-z","article-title":"CD57 in human natural killer cells and T-lymphocytes","volume":"65","author":"Kared","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2021.108830_bb0130","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.4049\/jimmunol.174.10.6088","article-title":"Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T lymphocytes during active, latent, and resolved infection and its relation with CD57","volume":"174","author":"Ibegbu","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108830_bb0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.clim.2021.108830_bb0140","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1016\/j.transproceed.2009.09.072","article-title":"A significant expansion of CD8+ CD28- T-suppressor cells in adult-to-adult living donor liver transplant recipients","volume":"41","author":"Lin","year":"2009","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.clim.2021.108830_bb0145","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T-cell exhaustion: characteristics, causes and conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.clim.2021.108830_bb0150","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621001674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621001674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:05:07Z","timestamp":1761494707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661621001674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":30,"alternative-id":["S1521661621001674"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2021.108830","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular changes in eculizumab early responders with generalized myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2021.108830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108830"}}